NCT05886660View on ClinicalTrials.gov

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Motion Sickness, SpaceMotion SicknessSea Sickness
Interventions
DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel.

DRUG

Placebo Nasal Gel

Subjects will self-administer Placebo Nasal Gel.

DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.

DRUG

Placebo Nasal Gel

"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."

Trial Locations (1)

77058

RECRUITING

NASA Johnson Space Center Neuroscience Laboratory, Houston

All Listed Sponsors
collaborator

National Aeronautics and Space Administration (NASA)

FED

lead

Repurposed Therapeutics, Inc.

INDUSTRY